Switzerland-based genomics technology provider Sophia Genetics, which counts telecommunications firm Swisscom among its shareholders, has raised $77m in funding from new and existing investors.
Investment firm Generation Investment Management led the round, which included private equity firm Idinvest Partners, venture capital firm Balderton Capital and Alychlo, the investment vehicle for pharmaceutical entrepreneur Marc Coucke.
Founded in 2011, Sophia has developed a clinical genomics analytics platform intended to help healthcare professionals diagnose and treat patients for cancer and hereditary disorders by more thoroughly analysing genomic and radiomic data. It also provides a network that enables users to share genomic data.
Jurgi Camblong, CEO and founder of Sophia Genetics, said: “Since we founded the company, our goal has been to help make the global healthcare system more sustainable.
“By helping clinical researchers leverage their expertise and work together as a community, patients all over the world can receive equal access to better care.”
Sophia said the round boosted its overall funding to approximately $140m, and the proceeds will be used to expand the community of hospitals using its technology and grow its presence in the US as it looks to increase the size of its team.
The company completed a $30m series D round in 2017 that was led by Balderton and included 360º Capital Partners, Invoke Capital and Alychlo.
Swisscom had participated in a $13.8m series B round for Sophia in 2014 that was led by Invoke and backed by Endeavour Vision, before Marc Coucke led the company’s $15m series C round the following year.